Search

Displaying results 2171 - 2180 of 4300 in total
  1. Drug

    Human papillomavirus type 52 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10313
    ApprovedInvestigational

    (VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs. … It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles

  2. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)

  3. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    [A235830,A241995] It received its first full approval in South Korea in September 2021,[A241995] followed by the EU in November 2021.[L39130]

  4. Drug

    Pepsin

    go.drugbank.com/drugs/DB13198
    ApprovedWithdrawn

    Soon afterward, it was shown that these protein nutrients were cleaved by pepsin to products called _peptones_ [A32603]. … Pepsin is approved by the FDA and is used in food at levels not to exceed current good manufacturing practice [L2363].

  5. Drug

    Pentaerythritol tetranitrate

    go.drugbank.com/drugs/DB06154
    ApprovedWithdrawn

    It is recognized by the FDA to be a coronary vasodilator in the treatment of heart conditions such as angina [L2395]. … It is formed by reacting pentaerythritol (C5H12O4), an alcohol commonly used in paints and varnishes, with nitric acid (HNO2). The reacting solution is chilled to precipitate the PETN.

  6. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    Myasthenia gravis (MG) is an autoimmune disorder characterized by significant muscle weakness - particularly in the eye, throat, and extremities - caused by autoantibodies attacking the neuromuscular junction … [L39509] By antagonizing this interaction, efgartigimod alfa prevents this recycling phase and thus decreases the half-life of IgG, effectively lowering circulating levels of IgG autoantibodies against

  7. Drug

    Dimercaprol

    go.drugbank.com/drugs/DB06782
    Approved

    Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects. … Dimercaprol is a traditional chelating agent developed by British biochemists at Oxford University during World War II.

  8. Drug

    Elinzanetant

    go.drugbank.com/drugs/DB18968
    ApprovedInvestigational

    [A274198] On July 23, 2025, it was approved by Health Canada to treat moderate to severe vasomotor symptoms (VMS) associated with menopause. … [L53798] By blocking receptor signaling on kisspeptin/neurokinin B/dynorphin (KNDy) neurons, which are hyperactivated due to estrogen decline in menopause, elinzanetant modulates neuronal activity involved

  9. Drug

    Avelumab

    go.drugbank.com/drugs/DB11945
    ApprovedInvestigational

    [A261496] Avelumab was first approved by the FDA on March 23, 2017. … [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126] and Health Canada,[L48171] respectively.

  10. Drug

    Phenoxyethanol

    go.drugbank.com/drugs/DB11304
    ApprovedInvestigational

    Phenoxyethanol has been classified as an antimicrobial and preservative by Health Canada [L2623]. … It is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621].